Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 45

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 45
---
ATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

(In thousands)

(Unaudited)

 Number of Shares OutstandingAdditionalPaid-InCapitalAccumulatedDeficitAccumulatedOtherComprehensiveIncome  Common SharesTreasury SharesCommon StockTreasury StockTotalBalance at June 30, 202547,691 (2,793)$48 $(75,515)$1,035,563 $(206,391)$4,062 $757,767 Exercise of stock options1 — — — 12 — — 12 Vested restricted stock units43 — — — (1)— — (1)Common stock withheld for employee withholding tax liabilities on vested restricted stock units— — — — (7)— — (7)Stock-based compensation— — — — 13,978 — — 13,978 Purchase of treasury stock, inclusive of excise tax and broker fees— (1,976)— (50,028)— — — (50,028)Other comprehensive income (Note 11)— — — — — — 61 61 Net income— — — — — 5,432 — 5,432 Balance at September 30, 202547,735 (4,769)$48 $(125,543)$1,049,545 $(200,959)$4,123 $727,214  

Number of Shares OutstandingAdditionalPaid-InCapitalAccumulatedDeficitAccumulatedOtherComprehensiveIncomeCommon SharesTreasury SharesCommon StockTreasury StockTotalBalance at June 30, 202446,954 (837)$47 $(25,121)$983,178 $(78,931)$105 $879,278 Vested restricted stock units31 — — — — — — — Common stock withheld for employee withholding tax liabilities on vested restricted stock units— — — — (32)— — (32)Stock-based compensation— — — — 13,230 — — 13,230 Other comprehensive income (Note 11)— — — — — — 573 573 Net loss— —